{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:46:25Z","timestamp":1793213185032,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T00:00:00Z","timestamp":1611792000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.esmoop.2021.100065","type":"journal-article","created":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T23:39:47Z","timestamp":1614641987000},"page":"100065","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["First-line daratumumab shows high efficacy and tolerability even in advanced AL amyloidosis: the real-world experience"],"prefix":"10.1016","volume":"6","author":[{"given":"G.","family":"Jeryczynski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Antlanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Duca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Binder-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Simonitsch-Klupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Bonderman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Kain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.-T.","family":"Krauth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Agis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2021.100065_bib1","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/978-3-319-40320-5_15","article-title":"Immunoglobulin light chain systemic amyloidosis","volume":"169","author":"Dispenzieri","year":"2016","journal-title":"Cancer Treat Res"},{"issue":"9","key":"10.1016\/j.esmoop.2021.100065_bib2","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100065_bib3","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jacc.2016.04.035","article-title":"Cardiac amyloid load: a prognostic and predictive biomarker in patients with light-chain amyloidosis","volume":"68","author":"Kristen","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.esmoop.2021.100065_bib4","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1080\/13506129.2017.1385453","article-title":"Pitfalls in conducting prospective trials in stage III cardiac amyloidosis - experience from the REVEAL study","volume":"24","author":"Phillips","year":"2017","journal-title":"Amyloid"},{"key":"10.1016\/j.esmoop.2021.100065_bib5","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.critrevonc.2016.01.004","article-title":"Immunomodulatory drugs in AL amyloidosis","volume":"99","author":"Jelinek","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"issue":"13","key":"10.1016\/j.esmoop.2021.100065_bib6","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.esmoop.2021.100065_bib7","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1182\/blood-2016-06-722496","article-title":"First report of safety and efficacy of daratumumab in 2 cases of advanced immunoglobulin light chain amyloidosis","volume":"128","author":"Sher","year":"2016","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.esmoop.2021.100065_bib8","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1182\/blood-2017-01-763599","article-title":"Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis","volume":"130","author":"Kaufman","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.esmoop.2021.100065_bib9","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/bjh.15455","article-title":"Daratumumab proves safe and highly effective in AL amyloidosis","volume":"185","author":"Khouri","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.esmoop.2021.100065_bib10","unstructured":"Kastritis E, Palladini G, Minnema MC, et\u00a0al. Subcutaneous daratumumab\u00a0+ cyclophosphamide, bortezomib, and dexamethasone (CyBorD) in patients with newly diagnosed light chain (AL) amyloidosis: primary results from the phase 3 ANDROMEDA study. EHA Late breaking abstract LB2604 2020. https:\/\/library.ehaweb.org\/eha\/2020\/eha25th\/303396\/efstathios.kastritis.subcutaneous.daratumumab.2B.cycl%20ophosphamide.bortezomib.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Amedia%3D3%2Ace_i."},{"issue":"1","key":"10.1016\/j.esmoop.2021.100065_bib11","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood.2019004460","article-title":"Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA","volume":"136","author":"Palladini","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.esmoop.2021.100065_bib12","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1002\/ajh.25819","article-title":"Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment","volume":"95","author":"Gertz","year":"2020","journal-title":"Am J Hematol"},{"issue":"18","key":"10.1016\/j.esmoop.2021.100065_bib13","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","article-title":"Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis","volume":"22","author":"Dispenzieri","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"issue":"17","key":"10.1016\/j.esmoop.2021.100065_bib14","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1182\/blood-2012-12-473066","article-title":"A\u00a0European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis","volume":"121","author":"Wechalekar","year":"2013","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.esmoop.2021.100065_bib16","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1038\/leu.2012.100","article-title":"Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis","volume":"26","author":"Comenzo","year":"2012","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.esmoop.2021.100065_bib17","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1038\/s41375-018-0060-x","article-title":"Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria","volume":"32","author":"Muchtar","year":"2018","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.esmoop.2021.100065_bib18","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3324\/haematol.13369","article-title":"Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis","volume":"94","author":"Bryce","year":"2009","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.esmoop.2021.100065_bib19","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2021.100065_bib20","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1182\/blood.2019004436","article-title":"Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase II study","volume":"135","author":"Sanchorawala","year":"2020","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.esmoop.2021.100065_bib21","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1182\/blood-2016-04-710822","article-title":"Pomalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 1 and 2 trial","volume":"128","author":"Sanchorawala","year":"2016","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.esmoop.2021.100065_bib22","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1182\/blood-2005-11-4385","article-title":"Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL","volume":"107","author":"Palladini","year":"2006","journal-title":"Blood"},{"issue":"10027","key":"10.1016\/j.esmoop.2021.100065_bib23","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.esmoop.2021.100065_bib24","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/bjh.14897","article-title":"Real world data of the impact of first cycle daratumumab on multiple myeloma and AL amyloidosis services","volume":"182","author":"Popat","year":"2018","journal-title":"Br J Haematol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702921000211?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702921000211?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:25:20Z","timestamp":1761855920000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702921000211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S2059702921000211"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100065","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First-line daratumumab shows high efficacy and tolerability even in advanced AL amyloidosis: the real-world experience","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100065","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100065"}}